Items where authors include "McParland, L"

Article

Holch, P, Absolom, KL orcid.org/0000-0002-5477-6643, Henry, AM orcid.org/0000-0002-5379-6618 et al. (18 more authors) (2023) Online symptom monitoring during pelvic radiotherapy: randomised pilot trial of eRAPID intervention. International Journal of Radiation: Oncology - Biology - Physics, 115 (3). pp. 664-676. ISSN 0360-3016

Love, SB, Cafferty, F, Snowdon, C et al. (33 more authors) (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23 (1). p. 757. ISSN 1745-6215

Velikova, G orcid.org/0000-0003-1899-5942, Absolom, K orcid.org/0000-0002-5477-6643, Hewison, J orcid.org/0000-0003-3026-3250 et al. (20 more authors) (2022) Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs. Programme Grants for Applied Research, 10 (1). pp. 1-110. ISSN 2050-4322

Absolom, K orcid.org/0000-0002-5477-6643, Warrington, L orcid.org/0000-0002-8389-6134, Hudson, E orcid.org/0000-0001-8758-7163 et al. (17 more authors) (2021) Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy. Journal of Clinical Oncology, 39 (7). pp. 734-747. ISSN 0732-183X

Franks, KN, McParland, L, Webster, J et al. (21 more authors) (2020) SABRTOOTH: A randomised controlled feasibility study of Stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection. European Respiratory Journal. ISSN 0903-1936

Gilbert, A, Drinkwater, K, McParland, L et al. (7 more authors) (2020) UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. European Journal of Cancer, 128. pp. 7-16. ISSN 0959-8049

Powell, JR, Murray, L orcid.org/0000-0003-0658-6455, Burnet, NG et al. (6 more authors) (2020) Patient Involvement in the Design of a Randomised Trial of Proton Beam Radiotherapy Versus Standard Radiotherapy for Good Prognosis Glioma. Clinical Oncology, 32 (2). pp. 89-92. ISSN 0936-6555

Ofuya, M, McParland, L, Murray, L orcid.org/0000-0003-0658-6455 et al. (3 more authors) (2019) Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy. Clinical and Translational Radiation Oncology, 19. pp. 17-26. ISSN 2405-6308

Renehan, AG, Muirhead, R, Berkman, L et al. (3 more authors) (2019) Early stage anal margin cancer: towards evidence-based management. Colorectal Disease. ISSN 1462-8910

O'Dwyer, JL orcid.org/0000-0002-7212-6089, Meads, DM orcid.org/0000-0003-1369-2483, Hulme, CT orcid.org/0000-0003-2077-0419 et al. (7 more authors) (2018) Cost‐Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. Arthritis Care and Research, 70 (3). pp. 462-468. ISSN 2151-464X

Teo, MTW, McParland, L, Appelt, AL orcid.org/0000-0003-2792-9218 et al. (1 more author) (2018) Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 100 (1). pp. 146-158. ISSN 0360-3016

Munir, T, Howard, DR orcid.org/0000-0003-3333-9783, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 31 (10). pp. 2085-2093. ISSN 0887-6924

Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215

Oughton, JB orcid.org/0000-0002-2047-804X, Collett, L, Howard, DR orcid.org/0000-0003-3333-9783 et al. (8 more authors) (2017) GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 18. 353. ISSN 1745-6215

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia, 31. pp. 2416-2425. ISSN 0887-6924

Snee, MP, McParland, L, Collinson, F et al. (10 more authors) (2016) The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Pilot and Feasibility Studies, 2 (1). 5.

Coates, LC orcid.org/0000-0002-4756-663X, Moverley, AR, McParland, L et al. (7 more authors) (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised, controlled trial. The Lancet, 386 (10012). pp. 2489-2498. ISSN 0140-6736

Coates, LC, Navarro-Coy, N, Brown, SR et al. (11 more authors) (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskeletal Disorders, 14. 101. ISSN 1471-2474

Collinson, FJ, Gregory, WM, McCabe, C et al. (11 more authors) (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC Cancer, 12. 598 - ? . ISSN 1471-2407

Monograph

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278

Conference or Workshop Item

Velikova, G orcid.org/0000-0003-1899-5942, Absolom, K orcid.org/0000-0002-5477-6643, Warrington, L et al. (11 more authors) (2020) Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)-An eHealth intervention during chemotherapy. In: 27th Annual Conference of the International Society for Quality of Life Research, 19-23 Oct 2020, Online.

Absolom, K orcid.org/0000-0002-5477-6643, Warrington, L, Holch, P et al. (9 more authors) (2020) Preliminary data from a randomised trial of online self-monitoring of adverse events during systemic therapy using eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice). In: British Psychosocial Oncology Society Annual Conference, 27-28 Feb 2020, Edinburgh.

Holch, P, Absolom, K orcid.org/0000-0002-5477-6643, Gibson, A et al. (12 more authors) (2020) A pilot randomised trial of online self‐monitoring of adverse events during pelvic radiotherapy using eRAPID (electronic patient self‐Reporting of Adverse‐events: Patient Information and aDvice). In: British Psychosocial Oncology Society Annual Conference 2020, 27-28 Feb 2020, Edinburgh, UK.

Royle, K-L, Martin, A orcid.org/0000-0002-2559-6483, Meads, D et al. (2 more authors) (2019) P-103: Considerations for statistical analysis when QALYs are a co-primary endpoint in a large phase II/III randomised controlled trial. In: 5th International Clinical Trials Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK.

Rawstron, A, Cohen, D, de Tute, R et al. (8 more authors) (2015) BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS. In: European Haematology Association Congress, 11-14 Jun 2015, Vienna, Austria.

Proceedings Paper

Munir, T, Howard, D orcid.org/0000-0003-3333-9783, McParland, L et al. (10 more authors) (2018) Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial. In: British Journal of Haematology. 58th Annual Scientific Meeting of the British Society for Haematology, 16-18 Apr 2018, Liverpool, UK. Wiley , p. 79.

Bestall, JC orcid.org/0000-0001-6765-6379, Franks, KN, Collinson, F et al. (7 more authors) (2017) Exploring Recruitment Factors in a Feasibility Trial of SABR versus Surgery. In: Journal of Thoracic Oncology. IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016), 03-07 Dec 2016, Vienna. Elsevier , S1093-S1093.

Sebag-Montefiore, D, Adams, R, Bell, S et al. (17 more authors) (2016) The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. In: Proceedings of the American Society for Radiation Oncology. 58th Annual Meeting of the American Society for Radiation Oncology, 25-28 Sep 2016. Elsevier , E164-E165.